Lumos Pharma (LUMO) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free LUMO Stock Alerts $2.31 -0.14 (-5.71%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 21, 2024 | finanznachrichten.deLumos Pharma, Inc.: Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024May 20, 2024 | globenewswire.comLumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024May 20, 2024 | americanbankingnews.comFY2024 EPS Estimates for Lumos Pharma, Inc. Lifted by Cantor Fitzgerald (NASDAQ:LUMO)May 16, 2024 | finance.yahoo.comLumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ...May 15, 2024 | finanznachrichten.deLumos Pharma, Inc.: Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsMay 14, 2024 | msn.comLUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | globenewswire.comLumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comLumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024April 18, 2024 | globenewswire.comLumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical MeetingsMarch 21, 2024 | markets.businessinsider.comLumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial OutcomesMarch 20, 2024 | globenewswire.comLumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042March 11, 2024 | sg.news.yahoo.comBAT set to sell stake in India's ITC stake as soon as this week, Bloomberg reportsMarch 10, 2024 | finance.yahoo.comLumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 9, 2024 | seekingalpha.comLumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finanznachrichten.deLumos Pharma, Inc.: Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateMarch 8, 2024 | finance.yahoo.comLumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | uk.finance.yahoo.comQ4 2023 Lumos Pharma Inc Earnings CallMarch 7, 2024 | investorplace.comLUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023March 7, 2024 | benzinga.comLumos Pharma: Q4 Earnings InsightsMarch 7, 2024 | globenewswire.comLumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateMarch 6, 2024 | benzinga.comEarnings Preview: Lumos PharmaMarch 6, 2024 | msn.comLumos Pharma FY 2023 Earnings PreviewFebruary 28, 2024 | finance.yahoo.comAxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of DirectorsFebruary 26, 2024 | globenewswire.comLumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024February 21, 2024 | msn.comExact Sciences (EXAS) Reports Q4 Loss, Tops Revenue EstimatesFebruary 5, 2024 | finance.yahoo.comLumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finance.yahoo.comLumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finance.yahoo.comIs Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?January 4, 2024 | marketwatch.comLumos Pharma Elevates Pitukcheewanont to Medical ChiefJanuary 4, 2024 | msn.comLumos Pharma promotes Pisit Pitukcheewanont to chief medical officerDecember 22, 2023 | benzinga.comLumos Pharma Stock (NASDAQ:LUMO) Dividends: History, Yield and DatesDecember 8, 2023 | markets.businessinsider.comBullish Outlook: Buy Rating on Lumos Pharma on Promising LUM-201 Trials for Pediatric Growth DeficiencyNovember 21, 2023 | finance.yahoo.comLumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone DeficiencyNovember 20, 2023 | finance.yahoo.comLumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in NovemberNovember 12, 2023 | morningstar.comLumos Pharma Inc LUMONovember 8, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Rhythm Pharmaceuticals (RYTM)November 7, 2023 | marketwatch.comStocks to Watch: Robinhood, Kyndryl, Lumos PharmaNovember 7, 2023 | marketwatch.comLumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All EndpointsNovember 7, 2023 | msn.comLumos stock rockets nearly 100% in after-hours trading on study updatesNovember 7, 2023 | msn.comLumos Pharma GAAP EPS of -$1.04 beats by $0.11, revenue of $7KSeptember 26, 2023 | markets.businessinsider.comPromising Results and Buy Rating for Lumos Pharma’s Groundbreaking Growth Hormone Stimulant: LUM-201September 26, 2023 | finance.yahoo.comLumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual MeetingSeptember 14, 2023 | finance.yahoo.comLumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual MeetingSeptember 7, 2023 | finance.yahoo.comLumos Pharma Announces Participation in Investor Conferences in SeptemberSeptember 6, 2023 | markets.businessinsider.comWhat 7 Analyst Ratings Have To Say About Lumos PharmaAugust 31, 2023 | msn.comLumos Pharma (LUMO) Price Target Increased by 10.18% to 20.60August 22, 2023 | finance.yahoo.comIndependent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic LandscapeAugust 15, 2023 | msn.comCantor Fitzgerald Maintains Lumos Pharma (LUMO) Overweight RecommendationAugust 15, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Lumos PharmaAugust 14, 2023 | finanznachrichten.deLumos Pharma, Inc.: Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update Get Lumos Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter. Email Address A once-in-a-century investment opportunity (Ad)It's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead. To get its name and ticker symbol for free - just click here. LUMO Media Mentions By Week LUMO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LUMO News Sentiment▼1.050.85▲Average Medical News Sentiment LUMO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LUMO Articles This Week▼31▲LUMO Articles Average Week Get Lumos Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MEI Pharma News Today Indaptus Therapeutics News Today Aptorum Group News Today Forte Biosciences News Today Cocrystal Pharma News Today Synlogic News Today BioVie News Today VBI Vaccines News Today Sol-Gel Technologies News Today CytoMed Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LUMO) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
